Invivyd (IVVD) Resumen de Acciones

Invivyd, Inc. es una empresa biofarmacéutica centrada en el descubrimiento, desarrollo y comercialización de soluciones basadas en anticuerpos para enfermedades infecciosas en Estados Unidos. Saber más

Análisis fundamental de IVVD
Puntuación del snowflake
Valoración	3/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Cotiza un 90.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 44.32%

Los beneficios han crecido un 11.3% al año en los últimos 5 años

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Precio de las acciones muy volátil durante los últimos 3 meses en comparación con el mercado US

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

IVVD Community Fair Values

Create Narrative

See what 84 others think this stock is worth. Follow their fair value or set your own to get alerts.

Invivyd

AnalystConsensusTarget

Based on Analyst Price Targets

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Key Takeaways Expansion of a skilled commercial team and new therapeutic programs positions Invivyd for broader market adoption, revenue growth, and reduced product concentration risk. Financial discipline and evolving regulatory support enhance sustainability, lower risk, and may fast-track product approvals and recurring revenue opportunities.

View narrative

US$10

74.1% infravalorado

77.22%

Revenue growth p.a.

435

Invivyd

AnalystHighTarget

Community Contributor

Rapid Antibody Advances Will Leverage Secular Pandemic Trends

Key Takeaways Invivyd's COVID-19 and next-generation antibody products are primed for durable, expanding revenue streams, potentially outpacing market expectations through breakthrough clinical benefits and guideline inclusion. The company's diversified pipeline, pandemic readiness focus, and operational efficiency position it for higher growth, stronger margins, and sustained earnings in a shifting healthcare landscape.

View narrative

US$5

48.2% infravalorado

112.11%

Revenue growth p.a.

Invivyd

AnalystLowTarget

Community Contributor

Regulatory Risks And Competition Will Impede Gains But Yield Promise

Key Takeaways Heavy reliance on emergency authorizations, regulatory uncertainties, and a narrow late-stage pipeline threaten Invivyd's long-term revenue stability and growth prospects. Heightened pricing pressures, high R&D costs, and formidable competition may erode profitability despite strong product demand and innovative advances in antibody engineering.

View narrative

US$1

159.0% sobrevalorado

95.47%

Revenue growth p.a.

View Stock Community

Competidores de Invivyd, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Invivyd
Precios históricos de las acciones
Precio actual de la acción	US$2.59
Máximo en las últimas 52 semanas	US$3.07
Mínimo de 52 semanas	US$0.35
Beta	0.62
Cambio en 1 mes	6.58%
Variación en 3 meses	112.30%
Cambio de 1 año	484.52%
Variación en 3 años	67.10%
Variación en 5 años	n/a
Variación desde la OPV	-87.60%

Noticias y actualizaciones recientes

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Nov 29

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Nov 18

Recent updates

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Nov 29

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Nov 18

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Oct 14

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Aug 22

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Apr 23 The development of next-generation antibodies could expand market reach and improve margins by lowering production and administration costs.

I See The Bull Case For Invivyd, But I'm Not Married To It

Feb 04

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Feb 01

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Jul 16

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Mar 29

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Oct 24

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Jul 04

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Mar 19

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Nov 19

Invivyd appoints interim CFO, makes headcount changes

Oct 13

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Sep 12

Adagio Therapeutics GAAP EPS of -$0.47

Aug 15

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Jul 30

Adagio names David Hering as permanent CEO and Director

Jul 05

Rentabilidad de los accionistas

	IVVD	US Biotechs	Mercado US
7D	-7.5%	-0.7%	-0.2%
1Y	484.5%	26.8%	17.1%

Rentabilidad vs. Industria: IVVD superó a la industria US Biotechs, que obtuvo un rendimiento del 26.8% el año pasado.

Rentabilidad vs. Mercado: IVVD superó al mercado US, que obtuvo un rendimiento del 17.1% el año pasado.

Volatilidad de los precios

Is IVVD's price volatile compared to industry and market?
IVVD volatility
IVVD Average Weekly Movement	20.4%
Biotechs Industry Average Movement	11.3%
Market Average Movement	6.4%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	2.9%

Precio estable de las acciones: El precio de las acciones de IVVD ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de IVVD ha disminuido de 37% a 20% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2020	100	Bill Duke	invivyd.com

Invivyd, Inc. es una empresa biofarmacéutica dedicada al descubrimiento, desarrollo y comercialización de soluciones basadas en anticuerpos para enfermedades infecciosas en Estados Unidos. La cartera de productos de la empresa incluye PEMGARDA (pemivibart) inyectable, un anticuerpo monoclonal (mAb) en investigación de semivida prolongada para la prevención de la COVID-19 en adultos y adolescentes; VYD2311, un candidato a mAb, que se encuentra en estudios preclínicos para la prevención o el tratamiento de la COVID-19; y Adintrevimab, que está en ensayos clínicos de fase 2/3 para la prevención y el tratamiento de la COVID-19. También tiene candidatos en fase de descubrimiento para la prevención de la gripe estacional y la COVID-19.

Resumen de fundamentos de Invivyd, Inc.

¿Cómo se comparan los beneficios e ingresos de Invivyd con su capitalización de mercado?
Estadísticas fundamentales de IVVD
Capitalización bursátil	US$603.79m
Beneficios(TTM)	-US$59.86m
Ingresos (TTM)	US$50.04m

12.1x

Ratio precio-ventas (PS)

-10.1x

Ratio precio-beneficio (PE)

¿Está IVVD sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IVVD
Ingresos	US$50.04m
Coste de los ingresos	US$3.33m
Beneficio bruto	US$46.71m
Otros gastos	US$106.57m
Beneficios	-US$59.86m

Últimos beneficios comunicados

Sep 30, 2025

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.26
Margen bruto	93.34%
Margen de beneficio neto	-119.63%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado IVVD a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/12/30 20:03
Precio de las acciones al final del día	2025/12/29 00:00
Beneficios	2025/09/30
Ingresos anuales	2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Invivyd, Inc. está cubierta por 6 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Thomas Shrader	BTIG
Joshua Schimmer	Cantor Fitzgerald & Co.
Jason Kolbert	D. Boral Capital LLC.

Invivyd (IVVD) Resumen de Acciones

Recompensas

Análisis de riesgos

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Rapid Antibody Advances Will Leverage Secular Pandemic Trends

Regulatory Risks And Competition Will Impede Gains But Yield Promise

Competidores de Invivyd, Inc.

Keros Therapeutics

Geron

Kura Oncology

ARS Pharmaceuticals

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Recent updates

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $124.9994 million.

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Invivyd, Inc. Appoints Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At Recover-TLC Workshop

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $49.997866 million.

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Invivyd, Inc. has filed a Follow-on Equity Offering.

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA®? (Pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG

Invivyd, Inc. Aligns with U.S. FDA on Rapid Pathway to Full Approval of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long Covid and Covid-19 Post-Vaccination Syndrome

Invivyd, Inc. Announces Positive Full Phase 1/2 Clinical Data for VYD2311, A Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 Pemivibart Clinical Trial

Invivyd, Inc. Announces Inclusion of PEMGARDA (Pemivibart) in National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd, Inc. Commends FDA Focus on Contemporary Evidence in Evaluating Medical Interventions to Prevent Covid-19

Invivyd, Inc. Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies for Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors

Invivyd, Inc. Auditor Raises 'Going Concern' Doubt

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA™? (Pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Invivyd, Inc. Announces Resignation of Sara Cotter from the Board of Directors

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers

Invivyd, Inc. Withdraws Financial Guidance for the Year 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants

Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data

Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19